Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation

Blood (2023) 142 (Supplement 1): 4657.

https://doi.org/10.1182/blood-2023-181661

Published: 2023

Journal Articles

Venetoclax in Combination with Pediatric-Inspired Chemotherapy in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of a Phase I Trial

Yannis K. Valtis, Mark Blaine Geyer, Martina Torres, Mackenzie Grogan, Madhulika Shukla, Eytan M. Stein, Jae H. Park

Blood (2023) 142 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2023-181122

Published: 2023

Journal Articles

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav Gupta, Prabhakar Borge, Ellin Berman, Mark Blaine Geyer, Aaron D. Goldberg, Tamanna Haque, Raajit K. Rampal, Jae H. Park, Lindsey E. Roeker, Martin S. Tallman, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 1519.

https://doi.org/10.1182/blood-2023-182012

Published: 2023

Journal Articles

Chemotherapy-Sparing Induction Followed By Consolidation and Maintenance with Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Primary Endpoint Results from the Blissphall Study

Mark Blaine Geyer, John Mascarenhas, Marissa Smith, Shakira Pascual, Anmol Shah, Michael R. Silvestrone, Tina Czaplinska, Kathryn Johnson, Meghan C. Thompson, Jae H. Park

Blood (2023) 142 (Supplement 1): 1510.

https://doi.org/10.1182/blood-2023-173551

Published: 2023

Journal Articles

Ruxolitinib Promotes Clinical Responses in Large Granular Lymphocytic Leukemia Via Suppression of JAK/STAT-Dependent Inflammatory Cascades

Blood (2023) 142 (Supplement 1): 183.

https://doi.org/10.1182/blood-2023-181922

Published: 2023

Journal Articles

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Mark Blaine Geyer, MD, Ellen K. Ritchie, MD, Arati V. Rao, MD, M. Isabella Cazacu, Shreya Vemuri, Martin S. Tallman, MD, Dan Douer, MD, Jae H. Park, MD

Blood (2018) 132 (Supplement 1): 4013.

https://doi.org/10.1182/blood-2018-99-115486

Published: 2018

Journal Articles

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Mark Blaine Geyer, MD, Patrick W. Burke, MD, Amber C. King, PharmD, BCOP, Michael J. Mauro, MD, Martin S. Tallman, MD, Ross L. Levine, MD, Charles J. Sherr, MD PhD, Dan Douer, MD, Jae H. Park, MD

Blood (2018) 132 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2018-99-110537

Published: 2018

Journal Articles

Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies

Gunjan L. Shah, MDMS, Jae H. Park, MD, Craig S. Sauter, MD, Elaine Duck, RN MS MA, Elizabeth Halton, NP-BC AOCNP, Maria Lia Palomba, MD, Connie Lee Batlevi, MD, Anas Younes, MD, Mark Blaine Geyer, MD, Eric L. Smith, MD PhD, Sham Mailankody, MBBS, Elena Mead, MD, Bianca Santomasso, MD PhD, Miguel-Angel Perales, MD, Paul Sabbatini, MD, Sergio Giralt, MD, Renier J. Brentjens, MD PhD, Peter Bach, MD

Blood (2018) 132 (Supplement 1): 616.

https://doi.org/10.1182/blood-2018-99-114093

Published: 2018

Journal Articles

Blinatumomab Administered Concurrently with Oral Tyrosine Kinase Inhibitor Therapy Is a Well-Tolerated Consolidation Strategy and Eradicates Measurable Residual Disease in Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Amber C. King, PharmD, BCOP, Jeremy Pappacena, PharmD, BCOP, Martin S. Tallman, MD, Jae H. Park, MD, Mark Blaine Geyer, MD

Blood (2018) 132 (Supplement 1): 1414.

https://doi.org/10.1182/blood-2018-99-113162

Published: 2018

Journal Articles

Hypofibrinogenemia and Disseminated Intravascular Coagulation Rarely Complicate Treatment-Naive Acute Lymphoblastic Leukemia

Charles Gaulin, MBBS, Angela Chan, MSN, AGPCNP-BC, Mark Blaine Geyer, MD, Jae H. Park, MD, Simon Mantha, MDMPH, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 1217.

https://doi.org/10.1182/blood-2018-99-110741

Published: 2018

Journal Articles

Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1523.

https://doi.org/10.1182/blood-2018-99-112591

Published: 2018

Journal Articles

Clinical and Pathological Features of B-Cell Acute Lymphoblastic Leukemia Following Maintenance Treatment with Lenalidomide for Multiple Myeloma

Mark Blaine Geyer, MD, Brian C. Shaffer, MD, Heather Landau, MD, Hani Hassoun, MD, Christopher Famulare, MS, Mikhail Roshal, MDPhD, Ahmet Dogan, MD PhD, Maria E. Arcila, Jae H. Park, MD

Blood (2017) 130 (Supplement 1): 1285.

https://doi.org/10.1182/blood.V130.Suppl_1.1285.1285

Published: 2017

Journal Articles

Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL

Mark Blaine Geyer, MD, Jae H. Park, MD, Isabelle Riviere, PhD, Brigitte Senechal, PharmD, PhD, Xiuyan Wang, PhD, Terence J. Purdon, Michel W. Sadelain, MD PhD, Renier J. Brentjens, MD PhD

Blood (2016) 128 (22): 58.

https://doi.org/10.1182/blood.V128.22.58.58

Published: 2016

NARROW

A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation

Venetoclax in Combination with Pediatric-Inspired Chemotherapy in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of a Phase I Trial

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Chemotherapy-Sparing Induction Followed By Consolidation and Maintenance with Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Primary Endpoint Results from the Blissphall Study

Ruxolitinib Promotes Clinical Responses in Large Granular Lymphocytic Leukemia Via Suppression of JAK/STAT-Dependent Inflammatory Cascades

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies

Blinatumomab Administered Concurrently with Oral Tyrosine Kinase Inhibitor Therapy Is a Well-Tolerated Consolidation Strategy and Eradicates Measurable Residual Disease in Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Hypofibrinogenemia and Disseminated Intravascular Coagulation Rarely Complicate Treatment-Naive Acute Lymphoblastic Leukemia

Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia

Clinical and Pathological Features of B-Cell Acute Lymphoblastic Leukemia Following Maintenance Treatment with Lenalidomide for Multiple Myeloma

Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only